NCT04131309: Phase 2: EMN 22 - Daratumumab Monotherapy in Stage 3B Light Chain (AL) Amyloidosis
- Active, not recruiting
- Dec 19, 2019
- 1 min read
Updated: Feb 10, 2024
NCT04131309: Phase 2: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis
NCT04131309: Phase 2: A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed stage 3B light chain (AL) amyloidosis.
Sponsor
Collaborator
ClinicalTrials.gov Identifier: NCT04131309
Official Title: Phase 2 Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis
First Posted : October 18, 2019
Click here to see details on ClinicalTrials.gov
Drug: Daratumumab
Drug: Bortezomib Injection
Drug: Dexamethasone oral tablet
Locations
Europe
France
Greece
Italy
Netherlands